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lishment, the EBM was highlighted. In 2004, the EBM
subcommittee was established under the CMDA.
Chinese Medical Association. Since 2002, the Chinese
Medical Association recognized the value of EBM.
EBM in universities. Many other Chinese universities
have developed their university-based center for EBM,
including Beijng University, Fudan University, Lan
Zhou University, Guang Xi University of Medical Sci-
ences, and Zhe Jiang University. Several universities
have developed courses for EBM postgraduate and
undergraduate courses.
Conclusions
The birth and development of EBM in China was a
result of practical needs, governmental support, and
international efforts. The further development of EBM
will be full of challenge and opportunity. But we are
conﬁdent to promote further the development in
China. The EBM in China is part of the world efforts,
and the world involvement in EBM cannot be without
the Chinese role.
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Introduction
From the year 2000, the national drug expenditure has
seen an increase from RM346 million ($91 million) to
RM915 million ($241 million) in 2005. From the year
2004 to 2005, an increase of 13.3% was recorded [1].
Factors that may contribute to this increase include
increase in drug prices, a growing and aging popula-
tion, higher expectation of the public regarding equal-
ity in assessing therapy, long-term drug treatment and
polypharmacy, improvements in diagnosis and treat-
ment of diseases, and technological advancement that
produces newer expensive drugs [2,3].
Drug Registration and Regulation in Malaysia
A statutory body known as the Drug Control Author-
ity (DCA) is responsible to ensure that medicines mar-
keted in Malaysia are safe, efﬁcacious, and of quality.
This is done through a systematic registration, licens-
ing, and surveillance scheme which is part of a man-
datory product registration process. The National
Pharmaceutical Control Bureau is an organization
under the Pharmacy Division. It is responsible for the
Quality Assurance program and performs the opera-
tional function of the DCA. This include activities such
as product evaluation, product assessment (laboratory
testing), Good Manufacturing Practice inspections,
processing of product certiﬁcate and licences, postmar-
keting surveillance, and monitoring of Adverse Drug
Reaction.
Malaysian Ministry of Health (MOH)
Drug Formulary
InMalaysia, drugs that aremade available for use in the
public health-care system are controlled through the
MOH Drug Formulary. The MOH Drug List was ﬁrst
introduced in 1983 and contains a list of drugs that have
been approved for use in the MOH hospitals and
institutions. The use of nonformulary drugs requires
prior authorization and approval by the Director-
General of Health. The use of this formulary does not
include the private hospitals and teaching hospitals. By
the end of 2005, there were 1322 preparations listed in
the formulary. Drugs in the formulary are classiﬁed
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according to the World Health Organization (WHO)
Anatomical Therapeutic Chemical classiﬁcation and a
Malaysian Drug Code is assigned to each particular
drug in the formulary for identiﬁcation purposes. The
drugs are listed according to their generic name and also
has the category of prescriber-authorized indicated. The
category of prescriber authorization are consultant/
specialists for speciﬁc indications only (A*), consultant/
specialists (A), consultant/specialists/family physician
specialists (A/KK), medical ofﬁcers (B), paramedical
staff (C), and paramedical staff doing midwifery (C+).
Depending on the therapeutic classes (there are 14
therapeutic classes), there may be 10–30 different drugs
available for each class. For example, there are more
than 26 nonsteroidal antiinﬂammatory drugs (consti-
tuting 13 active ingredients) and more than 60 antihy-
pertensive agents (constituting 34 active ingredients)
available presently. The MOH Drug Formulary has
varying degrees of prescriber restriction to control and
optimize drug use.
To review and update the Drug Formulary periodi-
cally, the MOH has a Health Drug List Review Panel
consisting of senior consultants and pharmacists from
the MOH. The drug review will be made based on
factors such as clinical advantage, best and current
treatment options, current and previous usage, pre-
scribing pattern, approved dosage and indication, and
cost of treatment. This panel also meets two to three
times in a year to consider proposal for new drugs, and
for deletion, alteration, addition of the drug/dosage
form/formulation/indication/category of prescriber for
the MOH Drug Formulary.
Challenges and Strategies for Improvement
Findings of a recent WHO/Health Action International
(HAI) report, “A Survey of Medicine Prices Availabil-
ity, Affordability and Price Components in Malaysia”
[4] showed that drug prices in Malaysia are generally
higher for both generics and innovator drugs when
compared with the international reference price. The
report also noted that there was low affordability for
all categories of drugs studied for both innovator
brands and generics. These were for common ailments
such as hypertension, asthma, and diabetes. As Malay-
sia practices free market for drug prices (i.e., does not
control the price of drugs), a market failure situation is
expected to occur because of the asymmetrical nature
of the information available coupled with the
monopoly and patent protection of the pharmaceutical
industries. It is important that the MOH implement
policies that can avoid this situation while at the same
time improving efﬁciency of the public health-care ser-
vices. A full pharmacoeconomic evaluation and con-
tinuously measuring outcome for selection of new
drugs are some of the strategies suggested. Other strat-
egies include generic substitution policy and using
standard treatment guidelines in clinical and policy
decision-making to ensure that the most cost-effective
and evidence-based alternatives are chosen.
In 2004, the National Medicine Use Survey was
undertaken by the MOH as a maiden landmark
project to obtain baseline data on the national drug
utilization pattern. The survey found that among the
top ﬁve drugs by therapeutic group utilization are
drugs for diabetes, beta-blockers, agents acting on the
rennin-angiotensin system, drugs for chronic obstruc-
tive airway disease, and systemic antihistamines [5].
Drug utilization patterns give early warning signs of
inappropriate drug use and are part of a continuous
quality improvement program.
Conclusion
A mandatory registration process has been imple-
mented since 1984 to ensure that medicines are safe,
efﬁcacious, and of quality. In Malaysia, the public
health facilities support 80% of the country’s patient
population and the drugs made available for use in the
public health care are controlled through the MOH
Drug Formulary. Faced with an increasing drug expen-
diture and limited resources, strategies involving drug
policy and formulary management must be considered
by the Malaysian MOH to ensure efﬁcient resource
allocation.
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